NORLUX Neuro-Oncology Laboratory
NORLUX represents a state-of-the art multidisciplinary research group with a critical mass of competitive scientists in neuro-oncology research.
activities
We aim to improve the treatment options for malignant brain tumors, with a focus on diffuse gliomas. With a radically translational approach to research, we work with patient samples and innovative patient-derived preclinical model systems that recapitulate the patient tumor. Our research investigates the cellular and molecular basis of gliomas, their capacity to invade the normal brain and escape therapy. Special areas of interests are tumor plasticity, tumor heterogeneity, tumor metabolism, immuno-oncology and pharmacogenomics.
projects
- Glioma patient avatars for personalized medicine
- Immuno-competent tumor organoids
- Personalized medicine and pharmacogenomics
- Glioblastoma heterogeneity, plasticity and tumor-microenvironment interactions
- IDH mutant glioma metabolism
- Novel regulators of glioma invasion
- Epigenetics, regulatory RNAs and functional genomics
- Harnessing endogenous RTK inhibitors for anti-cancer treatment
Projects & clinical trials
Featured team members
-
Monika
Dieterle Ph.D.
Research Engineer -
Sabrina
Fritah Ph.D.
Scientist -
Anna
Golebiewska Ph.D.
Group leader -
Eliane
Klein M.S.
Research Engineer -
Simone
Niclou Ph.D.
Director of Department of Oncology -
Anaïs
Oudin M.S.
Research Engineer -
Ilaria
Salvato
Scientific publications
-
Glioblastoma hijacks neuronal mechanisms for brain invasion – 31/07/2022
-
Elucidating tumour-associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency – 15/07/2022
-
Glioma progression is shaped by genetic evolution and microenvironment interactions – 09/06/2022
-
Interrogating intra-tumoral heterogeneity and treatment resistance in Glioblastoma patient-derived xenograft models using single cell RNA sequencing – 17/05/2022
-
Cancer cell heterogeneity and plasticity – 01/01/2021
-
Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson’s disease – 29/01/2022
-
PARK7/DJ-1 promotes pyruvate dehydrogenase activity and maintains Treg homeostasis during ageing – 01/01/2022
-
Federated Learning Enables Big Data for Rare Cancer Boundary Detection – 22/04/2022
-
Identifying and characterizing novel invasion-related genes in Glioblastoma – 25/03/2022
-
Enzymatic activity of glycosyltransferase GLT8D1 promotes human glioblastoma cell migration – 18/02/2022
-
Multiomic single nucleus RNA- and ATACSEQ profiling reveals regulators of glioma cell state diversity – 01/11/2021
-
XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase – 27/09/2021
-
Allergic airway inflammation impacts tumor take and delays experimental glioblastoma progression – 01/09/2021
-
Phenotypic heterogeneity and plasticity as resistance mechanisms in glioblastoma – 01/09/2021
-
Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas – 13/07/2021
-
Turning strength into weakness – 01/07/2021
-
Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry – 22/06/2021
-
Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors – 18/06/2021
-
Functional Analysis of Long Noncoding RNAs in Glioblastoma and Chemoresistance – 01/06/2021
-
Author Correction – 01/01/2021
Related News
-
Masters of Disguise: New tactics in the hunt for shapeshifting cancers
-
FNR Awards 2021: LIH researchers shine at centre-stage
-
Towards personalised treatment of recurrent brain tumours
-
New insights into Glioblastoma invasiveness
-
Advancing personalised cancer treatment through patient “avatars”
-
Advancing personalised cancer treatment through patient “avatars”
